Over the last five years, Lumere has partnered with hundreds of hospital administrators and physicians to help their health systems make better decisions about unnecessary variation and spend in medical device utilization, decisions that keep the patient’s interests front and center.
As we’ve worked with these healthcare leaders, we’ve also vigorously sought out and listened to their feedback. They told us that there was a need to apply our evidence-based analytical methodology to drug utilization. As a result, we recently launched our new Pharmacy Solutions to tackle unnecessary utilization and spend.
Looking toward our next innovation, our clients told us that they wanted to better understand how physician device selection affects care quality and patient outcomes. To address this, we knew we needed access to patient data that would help us uncover specific inefficiencies and measure improvements.
But before we could start analyzing patient data, we first needed to become compliant with the Health Insurance Portability and Accountability Act of 1996, better known as HIPAA. Will Danford, our chief technology officer, will be the first to tell you that this was not an easy (or inexpensive) decision. HIPAA requires us to conform to a lengthy, audited list of physical, network and process security measures to ensure that we can securely handle any patient health data.
Last month, our HIPAA auditors gave us the green light, and we’ve already begun working with some initial health system partners to extract the appropriate patient data from their electronic medical records. With this data in hand, our solutions will have a greater impact on improving the value of care being delivered. Along with reduction in drug and device spend, we can now measure the benefits that come with reducing lengths of stay, readmission rates and complication rates.
What’s next? Stay tuned. We know that there are many opportunities for us to help improve the entire continuum of patient care. All we need to do is keep listening.